This website is intended for UK Healthcare professionals only. Other UK residents please visit astrazeneca.co.uk

The MATTERHORN regimen is recommended by NICE

within its marketing authorisation for eligible patients in the UK with resectable gastric and gastro-oesophageal junction adenocarcinoma*^1,2

Therapeutic Indication: IMFINZI (durvalumab) in combination with FLOT chemotherapy as neoadjuvant and adjuvant treatment, followed by adjuvant IMFINZI monotherapy, is indicated for the treatment of eligible adults with resectable gastric and gastro-oesophageal junction adenocarcinoma¹

Always refer to the Summary of Product Characterictics before prescribing

*Please refer to the NICE guidance for full and further information.²

MATTERHORN perioperative treatment schedule³

The MATTERHORN regimen (for patients with a body weight of >30 kg): Perioperative IMFINZI + FLOT, followed by adjuvant IMFINZI monotherapy^1,3

Please refer to the IMFINZI Summary of Product Characteristics available here for further information regarding the posology, method of administration and more information.

The MATTERHORN trial was designed for patients to receive the full perioperative FLOT regimen, but also accounted for dose modifications per local clinical practice^1,3

AE, adverse event; BICR, blinded independent central review; FLOT, fluorouracil, leucovorin, oxaliplatin and docetaxel; GOJ, gastro-oesophageal junction; HCP, healthcare professional; IO, immuno‑oncology; MHRA, Medicines and Healthcare products Regulatory Agency; MoA, mechanism of action; NICE, National Institute for Health and Care Excellence; PD‑1, programmed cell death protein 1; PD‑L1, programmed death‑ligand 1; Q2W, every 2 weeks; Q4W, every 4 weeks; SmPC, Summary of Product Characteristics; R, randomised; RECIST, Response Evaluation Criteria in Solid Tumors.

IMFINZI. Summary of Product Characteristics. United Kingdom.
NICE. TA1160. Available at: https://www.nice.org.uk/guidance/TA1160. Accessed June 2026.
Janjigian YY, et al. N Engl J Med. 2025;393(3):217–230.
Janjigian YY, et al. Presented at ASCO 2025; 30 May–2 June; Chicago, IL. Abstract #LBA5.
Sheng J, et al. J Clin Pharmacol. 2017;57(Suppl 10):S26–S423.
Morgan C, et al. J Immunother Cancer. 2025;13(5):e011140.
Han Y, et al. Am J Cancer Res. 2020;10(3):727–742.

GB-77159 | August 2026

Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to AstraZeneca by visiting https://contactazmedical.astrazeneca.com/ or by calling ‌‌‌0‌‌‌8‌‌‌‌‌0‌‌‌‌0‌‌‌ ‌‌7‌‌‌‌‌‌8‌‌‌3‌‌‌ ‌‌0‌‌‌‌‌0‌‌‌‌3‌‌‌‌3‌‌‌.

This website was created for UK HCPs and has been designed to provide information to educate, empower and enable them in the great work they are doing for patients across a range of therapy areas. This website is intended for doctors, nurses, and pharmacists in the UK. Other UK residents please visit astrazeneca.co.uk.

Cookie Policy

The MATTERHORN regimen is recommended by NICE

MATTERHORN perioperative treatment schedule³

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

Thank you. We will be in touch

The MATTERHORN regimen is recommended by NICE

MATTERHORN perioperative treatment schedule3

Explore the IMFINZI MoA

Abbreviations and References

Enhance your knowledge, stay informed

Be the first to know. Hear about events, products and ways to support your patients.

Thank you. We will be in touch

MATTERHORN perioperative treatment schedule³